RSS-Feed abonnieren
DOI: 10.1055/s-0029-1241196
© Georg Thieme Verlag KG Stuttgart · New York
TSH Receptor Antibody (TRAb) Assays Based on the Human Monoclonal Autoantibody M22 are more Sensitive than Bovine TSH Based Assays
Publikationsverlauf
received 02.06.2009
accepted 09.09.2009
Publikationsdatum:
14. Oktober 2009 (online)

Abstract
Measurements of TSH receptor autoantibodies (TRAb) using assays based on the human monoclonal TSH receptor autoantibody M22 or bovine TSH have been compared in 136 adult patients. They suffered from Graves’ disease (GD, n=62), Hashimoto's thyroiditis (HT, n=26), or non-autoimmune hyperthyroidism (NAH, n=48) and were selected on the basis of undetectable, borderline or low TRAb levels (0.6–3 IU/l) as measured by TSH based TRAb assay (Dynotest® TRAKhuman from BRAHMS). The time interval between initial diagnosis of GD and TRAb determination was high and ranged from 1 month to 3.5 years (median: 2.3 years). Using the kit manufacturer's cutoff values, 53/62 (85.5%) of the selected group of GD patients were TRAb positive (>0.4 IU/l) by M22 based TRAb ELISA (Medizym® TRAb clone, Medipan) and 45/62 (72.6%) were TRAb positive (>1.5 IU/l) by TSH based TRAb assay. In the HT group, 9/26 (34.6%) sera were positive in the M22 based ELISA and all but one of these 9 were positive or borderline in the TSH based assay. ROC plot analysis of the GD group using the NAH group as reference showed that at 95% specificity, the bovine TSH based TRAb assay had a sensitivity of 62.9% (cutoff for positivity=1.64 IU/l) and the M22 based TRAb ELISA a sensitivity of 90.3% (cutoff for positivity=0.32 IU/l). Overall therefore, the M22 based Medizym® TRAb clone assay is more sensitive than the bovine TSH based Dynotest® TRAK human assay.
Key words
thyroid - autoantibodies - TSH receptor - Graves’ disease - Hashimotos’ disease
References
- 1
Rees Smith B, Sanders J, Furmaniak J.
TSH receptor antibodies.
Thyroid.
2007;
17
923-938
MissingFormLabel
- 2
Schott M, Scherbaum WA, Morgenthaler NG.
Thyrotropin receptor autoantibodies in Graves’ disease.
Trends Endocrinol Metab.
2005;
16
243-248
MissingFormLabel
- 3
Costagliola S, Morgenthaler NG, Hoermann R Badenhoop K, Struck J, Freitag D, Poertl S, Weglöhner W, Hollidt JM, Quadbeck B, Dumont JE, Schumm-Draeger PM, Bergmann A, Mann K, Vassart G, Usadel KH.
Second generation assay for thyrotropin receptor antibodies has superior diagnostic
sensitivity for Graves’ disease.
J Clin Endocrinol Metab.
1999;
84
90-97
MissingFormLabel
- 4
Schott M, Feldkamp J, Bathan C, Fritzen R, Scherbaum WA, Seissler J.
Detecting TSH-receptor antibodies with the recombinant TBII assay: technical and clinical
evaluation.
Horm Metab Res.
2000;
32
429-435
MissingFormLabel
- 5
Zöphel K, Wunderlich G, Koch R, Franke WG.
Measurement of thyrotropin receptor antibodies (TRAK) with a second generation assay
in patients with Graves' disease.
Nuklearmedizin.
2000;
39
113-120
MissingFormLabel
- 6
Zöphel K, von Landenberg P, Roggenbuck D, Wunderlich G, Kotzerke J, Lackner KJ.
Are porcine and human TSH receptor antibody measurements comparable?.
Clin Lab.
2008;
54
1-8
MissingFormLabel
- 7
Kamijo K.
TSH receptor antibody measurement in patients with various thyrotoxicosis and Hashimoto's
thyroiditis: a comparison of two-step assays, coated plate ELISA using porcine TSH
receptor and coated tube radioimmunoassay using human recombinant TSH receptor.
Endocr J.
2003;
50
113-116
MissingFormLabel
- 8
Bolton J, Sanders J, Oda Y, Chapman C, Konno R, Furmaniak J, Rees Smith B.
Measurement of thyroid-stimulating hormone receptor autoantibodies by ELISA.
Clin Chem.
1999;
45
2285-2287
MissingFormLabel
- 9
Sanders J, Jeffreys J, Depraetere H, Richards T, Evans M, Kiddie A, Brereton K, Groenen M, Oda Y, Furmaniak J, Rees Smith B.
Thyroid-stimulating monoclonal antibodies.
Thyroid.
2002;
12
1043-1050
MissingFormLabel
- 10
Sanders J, Evans M, Premawardhana LDKE, Depraetere H, Jeffreys J, Richards T, Furmaniak J, Rees Smith B.
Human monoclonal thyroid stimulating autoantibody.
Lancet.
2003;
362
126-128
MissingFormLabel
- 11
Rees Smith B, Bolton J, Young S, Collyer A, Weeden A, Bradbury J, Weightman D, Perros P, Sanders J, Furmaniak J.
A new assay for thyrotropin receptor autoantibodies.
Thyroid.
2004;
14
830-835
MissingFormLabel
- 12
Nakatake N, Sanders J, Richards T, Burne P, Barrett C, Dal Pra C, Presotto F, Betterle C, Furmaniak J, Rees Smith B.
Estimation of serum TSH receptor autoantibody concentration and affinity.
Thyroid.
2006;
16
1077-1084
MissingFormLabel
- 13
Liu C, Hermsen D, Dornberg J, Graeber C, Hautzel H, Duan Y, Xu KF, Liu CP, Mao XD, Cupisti K, Scherbaum WA, Schott M.
Comparison of M22 based ELISA and human TSH receptor based luminescence assay for
the measurement of thyrotropin receptor antibodies in patients with thyroid diseases.
Horm Metab Res.
2008;
40
479-483
MissingFormLabel
- 14
Spencer CA, Takeuchi M, Kazarosyan M.
Current status and performance goals for serum thyrotropin (TSH) assays.
Clin Chem.
1996;
42
140-145
MissingFormLabel
- 15
Zweig MH, Campbell G.
Receiver-operating characteristic ROC plots: a fundamental evaluation tool in clinical
medicine.
Clin Chem.
1993;
39
561-577
MissingFormLabel
- 16
Zöphel K, Grüning T, Roggenbuck D, Wunderlich G, Kotzerke J.
On Specificity of 2nd Generation TSH Receptor Autoantibody Measurements.
Clin Lab.
2008;
54
243-249
MissingFormLabel
- 17
Kamijo K, Ishikawa K, Tanaka M.
Clinical evaluation of 3rd generation assay for thyrotropin receptor antibodies: the
M22-biotin based ELISA initiated by Smith.
Endocr J.
2005;
52
525-529
MissingFormLabel
- 18
Kamijo K.
TSH receptor antibodies determined by the first, second and third generation assays
and thyroid-stimulating antibody in pregnant patients with Graves’ disease.
Endocr J.
2007;
54
619-624
MissingFormLabel
- 19
Ekins R, Edwards P.
On the meaning of sensitivity.
Clin Chem.
1997;
43
1824-1831
MissingFormLabel
- 20
Jensen E, Petersen PH, Blaabjerg O, Hansen PS, Hegedüs L.
Improved sensitivity of a thyrotropin receptor antibody assay.
Clin Chem.
2005;
51
2186-2187
MissingFormLabel
Correspondence
Priv-Doz. Dr. med. K. Zöphel
Department of Nuclear Medicine
Carl Gustav Carus Medical School
University of Technology
Dresden Fetscherstraße 74
01307 Dresden
Germany
Telefon: +49/351/458 138 79
Fax: +49/351/458 53 47
eMail: klaus.zoephel@uniklinikum-dresden.de